Assessment of immunogenic potential of Vero adapted formalin inactivated vaccine derived from novel ECSA genotype of Chikungunya virus

• Published in: Vaccine 2009-04, Vol.27 (18), p.2513-2522
• Main Authors: Tiwari, Mugdha, Parida, Manmohan, Santhosh, S.R, Khan, Mohsin, Dash, Paban Kumar, Rao, P.V. Lakshmana
• Format: Article
• Language: English
• Subjects: Allergy and Immunology; Animals; Antibodies, Viral - blood; Applied microbiology; Biological and medical sciences; Cell culture; Cercopithecus aethiops; Chikungunya; Chikungunya virus; Chikungunya virus - classification; Chikungunya virus - growth & development; Chikungunya virus - immunology; Cytokines; Cytokines - biosynthesis; Cytotoxicity; Dengue fever; Disease; Enzyme-Linked Immunosorbent Assay; Epidemics; Formaldehyde; Fundamental and applied biological sciences. Psychology; Genomes; Genotype; Genotype & phenotype; Humoral and CMI response; Immune response; Immune system; Immunization; Inactivated vaccine; Inactivation; Infections; Mice; Microbiology; Miscellaneous; Mutation; Neutralization; Neutralization Tests; Public health; R&D; Research & development; Serum free medium; Spinner culture; T-Lymphocytes, Cytotoxic - immunology; Vaccines; Vaccines, antisera, therapeutical immunoglobulins and monoclonal antibodies (general aspects); Vaccines, Attenuated - immunology; Vector-borne diseases; Vero Cells; Viral Vaccines - immunology; Virology
• ISSN: 0264-410X; 1873-2518
• DOI: 10.1016/j.vaccine.2009.02.062

Abstract The recent resurgence of Chikungunya virus (CHIKV) in India and Indian Ocean Islands with unusual clinical severity is a matter of great public health concern. Despite the fact that CHIKV resurgence is associated with epidemic of unprecedented magnitude, no approved licensed vaccine is currently available. In the present study, a Vero cell adapted purified formalin inactivated prototype vaccine candidate was prepared using a current Indian strain implicated with the explosive epidemic during 2006. The bulk preparation of the vaccine candidate was undertaken in microcarrier based spinner culture using cytodex-1 in virus production serum free medium. The inactivation of the virus was accomplished through standard formalin inactivation protocol. The mice were immunized subcutaneously with alhydrogel gel formulation of inactivated virus preparation. The assessment of both humoral and cell-mediated immune response was accomplished through ELISA, plaque reduction neutralization test (PRNT), microcytotoxicity assay and cytokine production assay. The results revealed that formalin inactivated vaccine candidate induced both high titered ELISA (1:51,200) and plaque reduction neutralizing antibodies (1:6400) with peak antibody titer being observed during 6–8 weeks of post-vaccination. In the absence of suitable murine challenge model, the protective efficacy was established by both in vitro and in vivo neutralization tests. Further assessment of cellular immunity through in vitro stimulation of spleenocytes from immunized mice revealed augmentation of high levels of both pro- and anti-inflammatory cytokines, indicating a mixed balance of Th1 and Th2 response. These findings suggest that the formalin inactivated Chikungunya vaccine candidate reported in this study has very good immunogenic potential to neutralize the virus infectivity by augmenting both humoral and cell-mediated immune response.